Infectious Disease Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Infectious Disease Diagnostics Market Trends and Insights

Escalating Prevalence and Resurgence of Infectious Diseases

Vector-borne illnesses are climbing, with dengue cases running 15% above the five-year average in early 2025.^{[1]Centers for Disease Control and Prevention, “Ongoing Risk of Dengue Virus Infections and Updated Testing Recommendations in the United States,” cdc.gov}Climate change is widening mosquito habitats, so providers now test for pathogens once restricted to the tropics. The World Health Organization classified mpox as a grade 3 emergency in August 2024, prompting a 160% jump in test demand over the prior year. Antimicrobial resistance adds pressure: the WHO’s 2024 priority list highlights 15 resistant bacterial families that need rapid diagnostics. As new threats surface, laboratories must refresh menus frequently, creating recurring revenue for firms across the infectious disease diagnostics market.

Growing Demand for Point-of-Care and At-Home Testing

Regulators are green-lighting consumer tests at pace. In August 2024 the FDA cleared the first OTC syphilis assay, ushering retail diagnostics into mainstream practice.^{[2]U.S. Food and Drug Administration, “FDA Marketing Authorization Enables Increased Access to First Step of Syphilis Diagnosis,” fda.gov} Syphilis incidence rose 80% from 2018 to 2022, so community pharmacies and e-commerce portals now stock rapid kits. Cepheid’s finger-stick hepatitis C test adds same-visit viral confirmation, closing care gaps in primary clinics. Payers value earlier therapy starts that reduce downstream costs, so reimbursement processes are catching up, even as coding complexity persists.

Continuous Innovation in PCR/NGS Platforms and Chemistries

CRISPR systems are approaching PCR-level sensitivity yet dispense with lengthy thermocycling steps. Portable devices such as the Dragonfly deliver 96.1% sensitivity for mpox without cold chain, fitting remote clinics. Isothermal nucleic-acid amplification bridges the gap between lab-based accuracy and field expediency. Metagenomic sequencing enables pathogen-agnostic detection, letting physicians identify unknown agents swiftly. Early adopters gain speed and menu breadth that cement competitive positioning in the infectious disease diagnostics market.

AI-Driven Laboratory Workflows for Testing

Machine-learning tools now auto-classify blood cultures and flag antimicrobial resistance patterns in minutes.^{[3]Phys.org, “CRISPR-Cascade Test Detects Bloodstream Infections in Minutes Without Amplification,” phys.org}Automated quality-control algorithms catch analytic drift and improve consistency. Fully robotic “dark” labs use AI to maintain throughput despite staffing gaps. Vendors who embed analytics directly into instruments or LIS platforms see faster adoption, because laboratories value productivity gains that offset shrinking reimbursement.

Fragmented and Inadequate Reimbursement Frameworks

Payers insist on stringent coding before honoring claims, and the added paperwork stretches cash cycles for smaller labs. Government fee schedules, especially in low- and middle-income countries, rarely cover the full cost of advanced molecular platforms, limiting uptake. Laboratories in such settings rely on donor programs, slowing commercial momentum despite clear clinical need. Harmonized payment models would unlock wider adoption across the infectious disease diagnostics market.

Budget Squeeze After COVID-19 Testing Wind-Down

COVID-19 volumes collapsed in 2024, cutting 17.6% off Abbott’s diagnostics sales. Public-health budgets likewise fell after USD 76 billion in emergency funds expired, slowing capital purchases. Many regional labs merged into larger networks to survive lower volumes, raising concentration but trimming near-term equipment orders.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Vector-Borne Diseases Drive Growth Beyond Respiratory Dominance

Respiratory panels held 19.85% of infectious disease diagnostics market share in 2025, yet vector-borne and emerging pathogens are set to climb at a 5.52% CAGR to 2031. A record 13 million dengue cases in 2024-2025 forced hospitals to expand test menus. Mpox, hepatitis, HIV self-tests, and AI-assisted tuberculosis assays broaden the clinical mix. The infectious disease diagnostics market size attached to vector-borne testing will keep rising as global mobility and climate change alter transmission zones.

Growth relies on rapid antimicrobial susceptibility tools for hospital-acquired infections and FDA OTC clearances for STI home kits. Laboratories value platforms that update quickly when the WHO adds bacteria to its resistance list; such flexibility strengthens vendor stickiness inside the infectious disease diagnostics market.

By Product & Service: Software Integration Accelerates Amid Hardware Maturity

Assays, kits, and reagents contributed 52.90% of infectious disease diagnostics market size in 2025 because consumables drive recurring revenue. Software and informatics, though smaller, will post the quickest 5.48% CAGR as labs digitize workflows. Instruments now compete on automation depth, sample-to-answer speed, and AI tie-ins rather than raw throughput alone.

Contract-testing services grow when hospitals outsource complex sequencing or drug-resistance panels. Cloud-based analytics link raw data to actionable reports, enhancing value per test. Vendors bundling reagents with informatics maintain share even as hardware margins tighten across the infectious disease diagnostics market.

By Technology: CRISPR Emergence Challenges PCR Dominance

PCR and qPCR kept 34.20% of infectious disease diagnostics market size in 2025, anchored by entrenched protocols and broad regulatory clearance. CRISPR assays will record a 5.18% CAGR because they reach PCR-grade sensitivity without full thermocycling steps. Isothermal NAAT devices and multiplex microarrays add flexibility for field teams.

Sequencing is pushing into routine care, aided by AI pipelines that shorten interpretation time. Pathogen-agnostic metagenomics is particularly useful for unexplained sepsis. The infectious disease diagnostics market benefits when multiple modalities converge in single instruments that cover screening, confirmation, and resistance profiling.

By End User: Home-Care Expansion Reshapes Market Dynamics

Hospitals and clinical labs retained 46.00% infectious disease diagnostics market share in 2025, yet OTC demand is rising fastest at 6.62% CAGR after FDA policies favor home testing. Reference labs absorb overflow and specialized NGS workloads, often contracting with regional facilities to standardize quality.

Telemedicine pairs with self-collection kits to widen access. Academic centers continue to pilot emerging tech and hand proven workflows to industry. As consumers take more control, vendors must design intuitive packaging and remote support to sustain adoption within the infectious disease diagnostics market.

By Test Setting: Over-the-Counter Testing Transforms Healthcare Access

Central laboratories still handle 67.90% of tests in 2025 because complex panels need stringent oversight. Yet OTC and at-home formats show a 6.74% CAGR, helped by CLIA-waived respiratory and STI minisystems. Regulators now demand embedded digital reporting to protect surveillance data as tests move outside labs.

Point-of-care molecular analyzers fit urgent-care clinics and ambulances, giving clinicians results in under 20 minutes. These shifts stretch supply chains but also introduce fresh channels for growth in the infectious disease diagnostics market.

By Sample Type: Swab Innovation Drives Non-Invasive Testing

Blood, plasma, and serum accounted for 42.95% of testing revenue in 2025, yet saliva and anterior-nares swabs are growing at 4.12% CAGR as collection becomes more comfortable. Multiplex saliva panels show sensitivity comparable to nasopharyngeal sticks. Urine NAATs expand STI screening, while AI-supported stool reviews improve parasite detection.

Improved buffers and extraction chemistries raise pathogen yield from low-volume samples. Portable devices now accept multiple matrices, boosting versatility and advancing decentralized adoption across the infectious disease diagnostics market.

Geography Analysis

North America generated 44.85% of global revenue in 2025, supported by established reimbursement rules, fast FDA clearances, and high routine screening volume. However, the region is now confronting budget compression as COVID-19 testing revenues fade, prompting labs to broaden menus and accelerate automation.

Asia-Pacific is projected to grow at a 5.20% CAGR to 2031 owing to infrastructure investment and rising infectious-disease burdens. Government programs in China, India, and Japan subsidize rapid dengue, mpox, and antimicrobial-resistance panels, which shortens adoption cycles. Digital health pilots link remote kits to teleconsults, increasing reach in rural regions.

Europe maintains steady demand and leads syndromic multiplex adoption. Fragmented reimbursement and data-privacy legislation slow cross-border digital-health scaling, yet antimicrobial-stewardship initiatives keep pressure on hospitals to deploy rapid diagnostics. Middle East and Africa markets remain smaller but are receiving donor-funded upgrades that create footholds for suppliers seeking geographic diversification within the infectious disease diagnostics market.

Regulatory Landscape

Regulatory requirements for infectious disease diagnostics are tightening around formal clinical evidence, quality systems, and traceability as testing expands into near-patient and at-home settings. In the United States, the FDA Final Rule for laboratory developed tests (LDTs) became effective on July 5, 2024, launching a phased approach to reduce enforcement discretion, with the first stage beginning May 6, 2025. This shift raises compliance expectations for hospital and reference labs that have relied on LDT pathways for specialty infectious disease assays, and it increases the value of cleared or authorized test menus for routine deployment.

In Europe, the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) continues to reshape market access for infectious disease IVDs through Notified Body oversight and EUDAMED requirements. Under Regulation (EU) 2024/1860, many legacy Class C tests must submit a formal conformity assessment application to a Notified Body by May 26, 2026, and secure a signed contract by September 26, 2026 to remain on the market. EUDAMED module use for device registration is mandatory for new IVDs from May 28, 2026. Separately, the WHO’s prequalification process changed effective January 1, 2026 by making performance evaluation a prerequisite for prequalification assessment, increasing upfront study and dossier work for suppliers targeting procurement-driven markets.

Value Chain Analysis

The infectious disease diagnostics value chain starts with critical raw materials (enzymes, primers/probes, monoclonal antibodies, nitrocellulose membranes, specialty plastics, and electronic or optical components), then moves through assay formulation and instrument manufacturing, software integration, regulatory validation, and distribution to hospitals, clinical labs, reference labs, decentralized sites, and retail or OTC channels. Post-pandemic product strategies increasingly bundle consumables with instruments and informatics. Service organizations also support installation, calibration, and workflow optimization as labs prioritize sample-to-answer automation and digital reporting.

Supply continuity remains a competitive differentiator because even small disruptions in specialized inputs can halt high-volume testing. In July 2024, the FDA flagged a shortage tied to Becton Dickinson’s BACTEC blood culture media packaging, underscoring how packaging and plastics can become bottlenecks for bloodstream infection workflows. Manufacturers are also managing regulatory constraints that limit rapid component substitution, since changes in critical suppliers often require re-validation and extend lead times. To reduce trade and logistics risk, production footprints are diversifying beyond traditional hubs, with more multi-regional manufacturing and sourcing across locations such as Malaysia, Vietnam, Thailand, Mexico, Costa Rica, and the Dominican Republic.

Market Opportunities and Future Outlook

White-space is widening in pathogen-agnostic and antimicrobial resistance (AMR) enabled workflows, where laboratories want faster identification and treatment guidance beyond traditional culture. Bruker’s July 2026 acquisition of the DISQVER clinical metagenomics platform expands sequencing-based infection detection capabilities, and bioMérieux’s integration work in sequencing and bioinformatics reinforces the same direction for complex infections such as unexplained sepsis. This creates room for vendors that can package metagenomics or targeted NGS with interpretation software that fits routine lab operations and reimbursement documentation.

Decentralized molecular testing and menu expansion under IVDR also support commercial openings for near-patient syndromic panels and higher-throughput automation, particularly where labor constraints and turnaround-time targets drive purchasing decisions. bioMérieux’s March 2026 IVDR CE-marking for BIOFIRE SPOTFIRE respiratory and sore throat panels shows continued platform migration into IVDR-compliant offerings, while BD’s November 2025 FDA 510(k) clearance and CE-IVDR certification for enteric bacterial panels on the BD COR System supports scale-up in gastrointestinal testing. WHO’s April 2026 R&D roadmaps for pathogen families under Collaborative Open Research Consortia (CORC) provide a clearer priority list for assay developers and partners, supporting coordinated development efforts across emerging threats. At the same time, tighter claims documentation requirements for multiplex panel reimbursement in the United States (MolDX guidance implemented in April 2026) increase the incentive for vendors to embed ordering support, medical-necessity documentation, and results reporting features into software and LIS-facing tools.